Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…Abstract Number: 1455 • ACR Convergence 2023
Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Background/Purpose: Cytomegalovirus (CMV) infection is classified as an opportunistic infection that occurs in autoimmune diseases. Systemic lupus erythematosus (SLE) is one of the most frequently…Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…Abstract Number: 1473 • ACR Convergence 2023
Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are…Abstract Number: 1464 • ACR Convergence 2023
Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the…Abstract Number: 1485 • ACR Convergence 2023
Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE…Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…Abstract Number: 1241 • ACR Convergence 2023
Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…Abstract Number: 1457 • ACR Convergence 2023
Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis
Background/Purpose: Up to 50% of patients suffering from systemic lupus erythematosus (SLE) develop lupus nephritis (LN) within the first 10 years of diagnosis and 5…Abstract Number: 1066 • ACR Convergence 2023
Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Background/Purpose: Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment. In suboptimal response, drug and anti-drug antibody…Abstract Number: 1433 • ACR Convergence 2023
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
- « Previous Page
- 1
- …
- 321
- 322
- 323
- 324
- 325
- …
- 2425
- Next Page »